Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries

Recruiting now · Phase 4

Conditions studied: Drug Clearance After Severe Burn Injury

In brief

Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.

Key facts

Study ID

NCT07465432

Run by

University of Tennessee

People needed

12

Starts

2026-02-16

Expected to finish

2027-02-28

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age ≥ 18 and ≤ 80 years old
• estimated CLCR (eCLCR) ≥ 60 mL/min via Cockcroft-Gault equation

You may not qualify if…

• KDIGO classification ≥ 1 at day of screening
• known HIV or HBV infection

Where it is running

• Regional One Health — Memphis, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.